Abiraterone, a CYP17A1 inhibitor, is used along with prednisone in patients with castration-resistant and castration-sensitive prostate cancer, yielding improved overall and disease-free survival. However, little is documented in the endocrinology literature about the incidences of the endocrine side effects of abiraterone. In this case series, we discuss the diagnosis and management of 3 prostate cancer patients who experienced mineralocorticoid excess and secondary adrenal insufficiency related to abiraterone and prednisone use.
Keywords: CYP17A1 inhibition; abiraterone; castration-resistant prostate cancer; mineralocorticoid excess syndrome; secondary adrenal insufficiency.
© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society.